CHICAGO, Oct 23 (Reuters) - Boston Scientific Corp (BSX.N: Quote, Profile, Research), battered by a drop in sales of implantable heart devices, on Tuesday said it sees early indications demand for drug-eluting stents will rebound as their benefits outweigh safety fears. “The evidence is beginning to mount for a recovery. We have not seen one yet, but the indicators are beginning to fall into place,” said Boston Scientific Chief Operating Officer Paul LaViolette.
